Company

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma
CAR-TCARsgen Therapeutics

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited (HKG: 2171) announced, in a voluntary business update, that CT0596, an allogeneic CAR T‑cell product targeting BCMA, has completed first patient dosing in its registrational Phase…

Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above

Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above

Sansure Biotech's Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Sansure Biotech’s Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
LupinNSE: LUPIN

Lupin Secures NMPA Approval for Oseltamivir Phosphate in China Through Yabao Pharmaceuticals Partnership

Gilead SciencesNASDAQ: GILD

Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus

AbbVie Secures CHMP Positive Opinion for MAVIRET in Acute Hepatitis C Treatment Across All Age Groups
AbbVieNYSE: ABBV

AbbVie Secures CHMP Positive Opinion for MAVIRET in Acute Hepatitis C Treatment Across All Age Groups

Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Succes
ADC / XDCAstraZeneca

Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success

Show More